SK Biopharmaceuticals: Epilepsies, Partial trials

The registry lists 13 Epilepsies, Partial studies with SK Biopharmaceuticals as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 4Phase 3 7No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedNCT02535091Phase 3Results posted
• A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedNCT01866111Phase 2Results posted
• Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset SeizuresCompletedNCT01397968Phase 2Results posted
• Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresCompletedNCT05067634Phase 3
• Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset SeizuresCompletedNCT04903314Phase 1
• Cenobamate Expanded Access Program (EAP)Approved for marketingNCT04513860
• An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.CompletedNCT00991757Phase 3
• An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset SeizuresCompletedNCT00744731Phase 3
• A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.CompletedNCT00740623Phase 3
• A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedNCT00433667Phase 3
• A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedNCT00425282Phase 3
• An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With EpilepsyCompletedNCT00210652Phase 2
• An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With EpilepsyCompletedNCT00210522Phase 2